This site uses cookies to simplify and improve your online experience.  You can find out more about cookies and how you can disable them by reading our Terms and Conditions. By continuing to browse this site you agree to our use of cookies on this device.

Close
Roche Navigation Menu Roche Resources : Roche Resources
  • Sign in
  • Logout
  • Search
Roche
  • Up
  • Home
  • Search
  • Close search

						
							

Searching

    • Home
    • Roche Medicines
      Roche Medicines Overview
      • Oncology
      • Avastin® (bevacizumab)
      • Kadcyla® (trastuzumab emtansine)
      • PERJETA® (pertuzumab)
      • PHESGO®▼(pertuzumab/trastuzumab)
      • TECENTRIQ®▼ (atezolizumab)
      • Rozyltrek▼(entrectinib)
      • Neuroscience
      • OCREVUS®▼ (ocrelizumab)
      • Immunology
      • RoACTEMRA® (tocilizumab)
      • Haematology
      • Gazyvaro® (obinutuzumab)
      • POLIVY®▼ (polatuzumab vedotin)
      • Rare Diseases
      • HEMLIBRA®▼ (emicizumab)
    • Therapy Areas
      Therapy Areas Overview
      • Oncology
      • Breast Cancer
      • Haematology
      • Haematology
      • Neuroscience
      • Neuroscience
    • Congress and Meetings
      Congress and Meetings Overview
    • HCP Materials
      HCP Materials Overview
    • FAQs
      FAQs Overview
    • Prescribing Information
      Prescribing Information Overview
      • Find out more about:
      • ALECENSA®▼(alectinib)
      • Avastin® (bevacizumab)
      • Esbriet® (pirfenidone)
      • GAZYVARO® (obinutuzumab)
      • HEMLIBRA®▼(emicizumab)
      • Herceptin® (trastuzumab) IV
      • Herceptin® (trastuzumab) SC
      • Kadcyla® (trastuzumab emtansine)
      • OCREVUS®▼ (ocrelizumab)
      • Perjeta® (pertuzumab)
      • Phesgo®▼(pertuzumab/trastuzumab)
      • Polivy®▼(polatuzumab vedotin)
      • RoACTEMRA® (tocilizumab) RA/GCA
      • RoACTEMRA® (tocilizumab) pJIA/sJIA
      • RoACTEMRA® (tocilizumab) CRS
      • Rozlytrek® ▼(entrectinib)
      • Tecentriq®▼ (atezolizumab) HCC
      • Tecentriq®▼ (atezolizumab) Lung Cancer
      • Tecentriq®▼ (atezolizumab) mTNBC
      • Tecentriq®▼ (atezolizumab) mUC
    • Adverse Events Reporting
      Adverse Events Reporting Overview
    Close

    1 - of results for ""

    No results

    This website is intended for healthcare professionals (HCPs) only. If you are an HCP, register free to access the full content.

    • Efficacy

      Read more

    • Dosing & administration

      Read more

    • Expert discussions

      Read more

    • Congresses and Meetings

      Highlights from the latest international and national congresses and Roche-organised meetings.

      Find out more

    • Gazyvaro® (obinutuzumab) in 1L FL
    • Prescribing Information
    • Efficacy
      • PFS
      • Higher risk patients
    • Safety & QoL
    • Dosing & administration
    • Expert discussions
    • More
      • Prescribing Information
      • Efficacy
      • Safety & QoL
      • Dosing & administration
      • Expert discussions

    You are here:

    1. Therapy Areas
    2. Haematology
    3. Gazyvaro® (obinutuzumab) in 1L FL

    Gazyvaro in first-line FL

    Find out more about:

    PFS in the GALLIUM study

    Efficacy in higher-risk patients (FLIPI scores ≥2)

    Learn about the impact Gazyvaro has on:

    AEs

    Secondary malignancies  IRRs

    IRRs

    QoL

    Resources to download:

    Dosing and administration guide

    Nurse checklist

    Listen to discussions on:

    The retrospective sub-analysis of the GALLIUM study in patients with FLIPI scores ≥2

    PET and MRD

    Chemotherapy backbone

    Frequently asked questions

    Indications1

    Follicular lymphoma (FL) 

    Gazyvaro in combination with chemotherapy, followed by Gazyvaro maintenance therapy in patients achieving a response, is indicated for the treatment of patients with previously untreated advanced FL.1

    Gazyvaro in combination with bendamustine followed by Gazyvaro maintenance is indicated for the treatment of patients with FL who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.1

    You can find information about Gazyvaro in R/R FL here.

    Chronic lymphocytic leukaemia (CLL)

    Gazyvaro in combination with chlorambucil is indicated for the treatment of adult patients with previously untreated CLL and with comorbidities making them unsuitable for full-dose fludarabine-based therapy.1

    You can find information about Gazyvaro in CLL here.

    1L, first-line; AE, adverse event; CLL, chronic lymphocytic lymphoma; FL, follicular lymphoma; FLIPI, Follicular Lymphoma International Prognostic Index; IRR, infusion-related reaction; MRD, minimal residual disease; PET, positron emission tomography; PFS, progression-free survival; QoL, quality of life; R/R, relapsed/refractory; SC, subcutaneous.

    Reference:

    1. Gazyvaro Summary of Product Characteristics.

     

    M-GB-00000090
    Date of preparation: July 2020

    Welcome to Roche Resources

    Roche Resources is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.

    I am a healthcare professional I am a member of the public
    • © 2021 Roche Products Limited
    • 19.01.2021
    • Terms and Conditions
    • Privacy Policy
    • Prescribing Information
    • Contact

    Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554. ▼Additional monitoring: Medicinal products associated with this symbol are subject to additional monitoring. Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. For biological medicines, healthcare professionals should report adverse reactions by brand name and batch number. This is a promotional website intended for HCPs, designed, built and funded by Roche Products Ltd. Commentary and other materials, including external links, posted on this site are not intended to amount to advice on which reliance should be placed. We therefore disclaim all liability and responsibility arising from any reliance placed on such materials by any visitor to our site, or by anyone who may be informed of any of its contents. M-GB-00002434 Date of Preparation January 2021.